Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated (NYSE: DGX) files reports with the U.S. Securities and Exchange Commission that provide formal insight into its operations as a medical laboratories company focused on diagnostic testing and diagnostic information services. On this page, investors can review Quest Diagnostics’ SEC filings alongside AI-powered tools that help explain the content and context of these documents.
Quest Diagnostics uses current reports on Form 8-K to disclose material events such as quarterly financial results and investor presentations. For example, the company has filed 8-Ks to announce results for specific quarters and to furnish presentation materials used at the J.P. Morgan Healthcare Conference, covering topics such as strategy, performance and market developments. These filings give investors structured access to information that the company shares with the market.
In addition to 8-Ks, users can expect to find Quest Diagnostics’ periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain detailed discussions of business segments, risk factors and financial condition. While these specific forms are not reproduced in the provided data, they are standard components of a public company’s SEC reporting and are accessible through this filings page.
The platform enhances these documents with AI-generated summaries that highlight key points, helping users navigate complex language and lengthy sections. For instance, AI tools can surface main themes from a 10-K, summarize quarterly performance from a 10-Q or clarify the significance of information furnished in an 8-K. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly.
Investors interested in governance, capital allocation and executive communications can use this page to monitor Quest Diagnostics’ regulatory disclosures, while AI assistance streamlines the process of reviewing and interpreting the company’s filings.
Quest Diagnostics director Robert B. Carter reported a small acquisition of company stock through a dividend reinvestment plan. On January 28, 2026, he acquired 6 shares of common stock at $183.51 per share. Following this routine reinvestment, he directly owns 2,704 shares of Quest Diagnostics common stock. The transaction was eligible for later reporting on Form 5, but he chose to report it early on this Form 4.
Quest Diagnostics director Vicky B. Gregg reported a small automatic share acquisition. On January 28, 2026, she acquired 67 shares of common stock at $183.513 per share through a broker-administered dividend reinvestment plan, bringing her direct holdings to 17,104 shares. The transaction was voluntarily reported early on Form 4, even though it was eligible for deferred reporting on Form 5 under Rule 16a-6.
DGX reported a Form 144 notice relating to proposed or completed sales of common stock by an insider. The filing shows a reported sale of 5,662 shares on
Quest Diagnostics reported an insider sale and recent restricted stock vesting. Catherine T. Doherty sold 26,165 Common shares on 02/13/2026 for $5,393,815.32. The filing also lists restricted stock vesting of 726 shares on 02/12/2026 and 707 shares on 02/14/2026, each labeled as Issuer compensation.
DGX filed a Form 144 indicating planned sales of common stock following restricted stock vesting. The notice lists 480 shares with a 02/12/2026 date and 631 shares with a 02/14/2026 date, with transactions routed through Fidelity Brokerage Services LLC.
Quest Diagnostics EVP Catherine T. Doherty reported an option exercise and related share sales. On 02/13/2026 she exercised 26,165 non-qualified stock options at
That day she sold 26,165 common shares in several open-market transactions at weighted average prices between
A shareholder of DGX has filed a notice under Rule 144 to sell 26,165 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 02/13/2026. The filing lists an aggregate market value of these shares of
Quest Diagnostics executive Patrick Plewman reported multiple stock transactions involving DGX shares. On January 28, 2026, he acquired 48 shares of common stock at $183.512 per share through a dividend reinvestment plan administered by his broker, bringing direct ownership to 15,381 shares.
On February 10, 2026, he exercised a non-qualified stock option for 5,662 shares of common stock at an exercise price of $121.805 per share and immediately sold 5,662 shares of common stock at $204 per share in an open-market transaction. After these transactions, he directly owned 15,381 shares of Quest Diagnostics common stock. The filing notes that the option exercise and sale were carried out under a pre-arranged Rule 10b5-1 sales plan.
A holder of DGX common stock has filed a notice of intent to sell 5,662 shares under Rule 144. The planned sale, through Fidelity Brokerage Services LLC on the NYSE, has an stated aggregate market value of $1,155,048.00.
The shares are part of DGX common stock, with 111,242,362 shares outstanding at the time referenced. The seller acquired these 5,662 shares on 02/10/2026 by exercising a stock option originally granted on 02/17/2021, and paid the purchase price in cash.
Quest Diagnostics reported strong 2025 results with net revenues of $11.04 billion, up 11.8% from 2024, and reported diluted EPS of $8.75, up 13.8%. Adjusted diluted EPS was $9.85, up 10.3%. Fourth quarter revenue rose 7.1% to $2.81 billion, with diluted EPS of $2.18 and adjusted diluted EPS of $2.42. Cash from operations for 2025 was $1.89 billion.
The company issued 2026 guidance for net revenues of $11.70–$11.82 billion, reported diluted EPS of $9.45–$9.65, and adjusted diluted EPS of $10.50–$10.70. The Board raised the quarterly dividend 7.5% from $0.80 to $0.86 per share, or $3.44 annually, and expanded the share repurchase authorization by $1 billion, on top of approximately $0.4 billion remaining as of December 31, 2025.